Therapy of a fatal murine cytomegalovirus infection with thymic humoral factor (THF-γ2) treated immune spleen cells

B. Rager-Zisman, F. Zuckerman, D. Benharroch, M. Pecht, Y. Burnstein, N. Trainin

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

Infection of mice with murine cytomegalovirus (CMV) presents a model for the study of the role of the immune system in the pathogenesis of human CMV. We performed adoptive transfer experiments to evaluate the prospects for enhancing the anti-viral potential of murine CMV immune spleen cells by THF-γ2. Adult BALB/c mice resistant to murine CMV become highly susceptible following immunosuppression by cyclophosphamide. Recipient mice were injected with murine CMV and cyclophosphamide concomitantly, and 24 h later adoptive transfers of syngeneic immune spleen cells were performed. We showed that passive transfers of murine CMV immune spleen cells prevented the development of a fatal disease in 38% of the recipient mice. Daily injections of murine CMV immune donor mice with THF-γ2 enhanced considerably (93%) the therapeutic potential of virus-specific immune cells. These experiments provide direct evidence for the antiviral capacity of THF-γ2 through its immunomodulatory effect on immune T cells.

Original languageEnglish
Pages (from-to)246-252
Number of pages7
JournalClinical and Experimental Immunology
Volume79
Issue number2
DOIs
StatePublished - 1 Jan 1990

Keywords

  • adoptive transfers
  • murine cytomegalovirus
  • thymic humoral factor

Fingerprint

Dive into the research topics of 'Therapy of a fatal murine cytomegalovirus infection with thymic humoral factor (THF-γ2) treated immune spleen cells'. Together they form a unique fingerprint.

Cite this